# Novo defends diversification push as CEO eyes deals beyond obesity

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-22 12:29 UTC · Category: Business · Sources: 6 · Current Velocity: 4.9

## Key People, Organizations & Locations
CEO, Novo

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| CNBC | Novo defends diversification push as CEO eyes deals beyond obesity | 2026-09-22 08:53 | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxNRW5sNWNBOW5VakRQcTk3OC1saVc3UlpMVzlxZkhvYjRLNEEwSjRJNXpHN3RtQmZlMHpLdi1vRHp3T0hicXo4LVM0N2dGdGtyc0NtLW9IR3VZVnJsbGdZeEFiRjBpTkJuY3RHT01fbzdtZ0VVR1dRdk5WT09Od1RLSzdiWFVDdTRLQ1F3d3U1dmRRNEI4?oc=5) |
| global.morningstar.com | Novo Nordisk: Stock Drops, But New Targets Look Similar to Our Projections | 2026-09-22 08:53 | [Source Link](https://news.google.com/rss/articles/CBMitgFBVV95cUxNcjQ5bjlwSHBGQmJVbmJaSUNpemJTeE9ERTBlek1iWGVDaUtYazFNU2ZXeXZNZkRMSHcxMzBraWJMd0VfYzl6cDB2d2hmS0ZWeENKVVZ6U1hzbGU4UDUtVHhhSFVHeW5ZUkVid1FxclY4UElSM1Y3dVI4OUFsS2VaSnlQbDczdXhGLVkwd3EyMzl1bXo1N2NvNUJVNi1FdFJTd1QzS3lGSmtaWkRIcW9BOUpoaUxjZw?oc=5) |
| Yahoo Finance | Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations | 2026-09-22 08:53 | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxObW1MTE5TUXJvVGQ5WlRWeTJKempMWFE2VnFlekRyTTlydHcyTXdwV3NSRUNqbUhMajNqSzhabDRBU3g1bkFDZlVhVDNvR1cwSEY5Zi1LSTgwdTU0RVNHYWRiQzNQeG9kaHdKNDBKeEs4NEdydVRpeEplYmpSc2t4NDhhTnp5VTRTTC1ablF1eVZrdw?oc=5) |
| endpoints.news | Novo’s CEO knows the drugmaker needs to build confidence | 2026-09-22 08:53 | [Source Link](https://news.google.com/rss/articles/CBMihgFBVV95cUxOam9yamlGenhLdTFmY1hubzRnTWR2NDUtbGR4XzFOWHdZUWVuY0o4bXJCbWw1RXJ0Mi1qVzVsNldPTGkxZXIwdjR4dl9JV3NaQjgwVGdYTjl5ZWZkdmhhb194YWoxaEVJV1hxTTFfc2RQWTR2QTBVZGZtY09iRHNTZ1loU1ljQQ?oc=5) |
| Yahoo Finance | Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy? | 2026-09-22 08:53 | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxQSzhMWUd2eTVuMG1XUDdnZmx0RTNJUC01TzhVd3lyZ3VhNFVERzM0aGlubUlheVVmZHhqTWZPQkJjOUJvLWhhemNKdTV4X1VmZlVyTFlMZnlwbnpTVW9TUUlxNEE1a09KeGlGWTJZdEM5WERHQU1WV0wwT09SYnFrS1hDc3VFMU1TMDZfT0xGeFo5dWdMbXNwbg?oc=5) |
| Yahoo Finance | Novo targets blockbuster-heavy 2030 but share slump signals unease | 2026-09-22 08:53 | [Source Link](https://news.google.com/rss/articles/CBMinAFBVV95cUxQWkxjSkw5dENvRElIYnp2bTZob2swNjNLT29wR0c3ZHlDdTVfRXkzZ3pRMENucVJRenZtaGVsOEFjZnhMb0w2Zi10bTFVQUYxUVA0QVVZcUkzSlgwc1hBX0YyVVI4Qkg2eGxMYUppTXpUcm1BTVYxd1hTV056RWpJYWhhYVNhelQ3M1pCbVNidWwzWmt4ZkItZkx0Mmk?oc=5) |
| The Times | Wegovy maker’s shares fall as blockbuster drugs plan disappoints | 2026-09-22 08:53 | [Source Link](https://news.google.com/rss/articles/CBMisgFBVV95cUxQMWZEc21BSEJ0eXNXcXV2WkRtMWFjUHMzcGU1VE1iOUFxMUQxYWxRQzNhU09yMFRQNXNlbmMtQmJabDNPelpXdlU4eHBiQkl3SzFDMVQzOVk4aTREb3ZiZjN4MmdJRjl0bHN2dW1nNEU2MGJHYlZXbHUwN3BlbTNkXzdtSTJLR3VfWXM0N1lVMzlDSkVmeDktMVFIdW9YR3pQdGZLZmRuS19iZ0tZcGJpZWt3?oc=5) |
| finance.yahoo.com | GLP-1 maker Novo Nordisk's big reveal leaves the City cold | 2026-09-22 08:53 | [Source Link](https://news.google.com/rss/articles/CBMijwFBVV95cUxNVEd6NUxoUHI0aGV4X0lyQjdZU3NxamgzWXUyNnU5ZTFONXkzNy1YQkxCX1E2TU1wUXh0ZmlkX3RrWTBnbTgzc0JyYVM1cFJTeHdQMWtvNDFEcGl3dUs0cFp1aUlQbElTbkVlNFk3b3lZeEFvd0ZWR1VNNmIzMGtDQk9nX2hjQUVSYU5Ua2dEOA?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-22/novo-defends-diversification-push-as-ceo-eyes-deals-beyond-obesity*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*